Through clinical trials research, NCI-Designated cancer centers such as the Stephenson Cancer Center (SCC) facilitate the translation of new ideas into direct benefit for cancer patients and the general public.
The SCC is a recognized national leader in the design and conduct of early- and late-phase clinical trials. It is currently one of just 32 NIH-funded Lead Academic Participating Sites (LAPS) in the NCI’s National Clinical Trials Network (NCTN), and it annually ranks among the top LAPS centers nationally for the number of patients participating in NCTN treatment and precision medicine trials. The SCC’s Early-Phase Clinical Research Unit, named the Oklahoma TSET Phase I Program in recognition of the Oklahoma Tobacco Settlement Endowment Trust’s support for cancer research, is a top 10 program nationally for the number of patients participating in early-phase clinical trials.
The SCC has a large and robust infrastructure to oversee all aspects of clinical research activities conducted at the cancer center, from the rigorous scientific review of new protocols to policies and procedures that ensure proper regulatory compliance, study coordination, patient safety, and data quality. Separate standing committees actively oversee protocol review and monitoring (PRMC) and data and safety monitoring (DSMC). Through its Investigator-Initiated Protocol Support Unit, the SCC assists clinical investigators with all aspects of developing new clinical trials protocols.
More information about these resources can be found via the links below: